4M Therapeutics joins MIT Startup Exchange

January 13, 2021

Skillman, New Jersey, USA — 4M Therapeutics Inc. (4MTx) has joined the Massachusetts Institute of Technology’s Startup Exchange. The Startup Exchange actively promotes collaboration and partnerships between MIT-connected startups and industry, exclusively members of MIT’s Industrial Liaison Program (ILP). MIT Startup Exchange and the ILP are integrated programs of MIT Corporate Relations.

“MIT-connected” startups are based on licensed MIT technology, or are founded by MIT faculty, staff, or alumni.

The industry side of the exchange is represented primarily by 240+ ILP member companies. Meetings between MIT Startup Exchange startups and industry are facilitated by program directors at MIT’s Industrial Liaison Program. Each program director manages a portfolio of ILP member companies, and their primary role is to match company research interests with relevant MIT faculty and researchers. Increasingly, on-campus agendas include MIT Startup Exchange startups, based on their potential to rapidly explore and assess new technologies.

4MTx is honored to be a member of MIT Startup Exchange. We look forward to engaging with ILP member companies and their representatives to help bring life-saving medicines to the most people as quickly as possible.

Learn more about MIT Startup Exchange

About 4M Therapeutics:

4M Therapeutics Inc. (4MTx) is a startup biotech company based on the belief that the study of human brain cells represents an important advance in neuroscience discovery. 4MTx has developed a pipeline of small molecules by studying their effects on brain cells derived from induced pluripotent stem cells. The initial focus is on bipolar disorder and Alzheimer's disease, conditions where enhancement of WNT protein expression can support neuroplasticity and neurogenesis. More information on 4MTx is available at www.4mtx.net.

4M Therapeutics Statement Regarding Forward-Looking Statements:

This announcement contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements

For additional inquiries, contact Ben Williams, Vice President of Corporate Development and Co-founder of 4M Therapeutics, ben@4mtx.net